Clinical trial begins for iPS cell-based therapy for Parkinson's disease (30 July 2018)

Published on

On 30 July, Kyoto University Hospital announced that it will begin a series of physician-initiated clinical trials for the treatment of Parkinson's disease using dopaminergic progenitors, which will be generated from induced pluripotent stem (iPS) cells. The trials will begin on 1 August, and has been designed in partnership with the University's Center for iPS Cell Research and Application (CiRA). Formal notification was submitted to the Pharmaceutical and Medical Devices Agency (PMDA) on 4 June 2018.

The project will be led by KyotoU Hospital Professor Ryosuke Takahashi, and involve the Hospital's three departments — Neurology, Neurosurgery, and Diagnostic Imaging and Nuclear Medicine — as well as a CiRA team headed by Principal Investigator Professor Jun Takahashi.

The team is committed to ensuring the safety and adequacy of the clinical procedures, with the goal of making the new, iPS cell-based treatment available to patients as soon as possible.

KyotoU Hospital Director Nobuya Inagaki introducing the study team

KyotoU Hospital Professor Ryosuke Takahashi presenting an overview of the trials

CiRA Professor Jun Takahashi responding to a reporter's question

Clinical trial details

  1. Procedures
    CiRA's stockpiled iPS cells (iPS Cell Stock for Regenerative Medicine) will be used to generate dopaminergic progenitors, which will then be transplanted into the brains of seven patients (allogeneic transplantation). To minimize the risk of immune rejection, the subjects will be treated with tacrolimus, an immunosuppressant commonly used following organ transplantation.

  2. Target condition
    Parkinson's disease

  3. Participation opportunities
    Those interested in taking part are advised to visit the following webpage (in Japanese,
    open until 30 September 2018 ):

Related link

Related departments & centers